MSF's Suerie Moon spoke in front of a US Senate Committee on promoting new treatments & cures for neglected diseases read more
NEW: The 13th Edition of Untangling the Web of Antiretroviral Price Reductions is now available download it here
VIDEO: MSF's community approach to treating malnutrition in Niger watch it here
WHO's work on the financing of medical research and development is given a fresh start read more
MSF Letter to GFATM on concerns over scale-up of AIDS treatment in light of Board of Directors Meeting read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
|
 |
|
 |
Company: Boehringer Ingelheim
Headquarters: Ingelheim, Germany
These are the drug patents we want Boehringer Ingelheim to put in the pool and why patients need them:
Nevirapine (NVP)
Brand name: Viramune
This drug is used by people starting out on antiretroviral therapy. Like other HIV drugs, it is taken in combination with other drugs. Putting this drug in the pool will open the way to simplified treatment for patients by creating more easy to take, three-in-one combination tablets.
Tipranavir (TPV)
Brand name: Aptivus
Tipranavir is a drug that can be used to treat children who have grown resistant to their original antiretroviral treatment. There are a very limited number of drugs of this class (known as protease inhibitors or PIs) produced in child dosages that are available in developing countries and putting the patents for this drug in the pool could help to increase the treatment options for treating children with HIV over two years of age
FATAL FLAWS: How Kenya's 2008 Anti-Counterfeit Act could endanger access to medicines 
Presenation: Missing ARVs for HIV/AIDS treatment in 2009 - Unitaid Patent Pool Briefing
HIV/AIDS treatment in developing countries: the battle for long-term survival has just begun
